AstraZeneca Investor Conference Presentation Deck
Strengthening scientific leadership
Extensive R&D investment in cutting-edge platforms and technology
'Growth Through Innovation'
investing in four areas to create the
greatest and swiftest impact on disease
●
●
●
●
●
Small molecules
PROTACS
Nanoparticles
Epigenetics
Cell-based therapeutics
CAR-T therapy
Macrophage therapy
TReg stabilisation
●
●
●
●
●
●
Enhancing our
understanding of
disease biology
Antibody therapeutics
Monoclonal
ADCs
Bispecifics
●
●
Better
predictions of
clinical success
Fragments
T-cell engagers
Peptide/protein therapeutics
Therapeutic proteins
Bicyclic peptides
Anticalin proteins
Pioneering
new approaches
to clinical
interventions
●
Nucleotide-based therapeutics
Antisense oligonucleotides
Oligonucleotide conjugates
Therapeutic gene editing
siRNA
mRNA
Creating the
next
generation of
therapeutics
●
Underpinned by advancements in Data, Al and Digital Health
> in vivo-expressed biologics
Viral vectors
DNA vectors
7 PROTACS = proteolysis targeting chimeras; ADCs = antibody-drug conjugates; CAR-T = chimeric antigen receptor (CAR) T-cell therapy; Treg = regulatory T-cell; siRNA = small interfering ribonucleic acid; mRNA = modified ribonucleic
acid; DNA = deoxyribonucleic acid; Al = artificial intelligence.
BView entire presentation